Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Implementation Will Be Overseen By Mylan’s Representative in the House

This article was originally published in RPM Report

Executive Summary

Mylan played a pivotal role in crafting the formula to create Generic Drug User Fees. The selection of Rep. Tim Murphy (R-Pa.) to chair the House Energy & Commerce Oversight Subcommittee should help assure that Mylan’s perspectives continue to play an important role.

Advertisement

Related Content

Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Culture Clash: U.S. FDA Tries to Re-educate Indian Firms on Processes And Accurate Reporting
Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting
Mylan’s Autor-de-Force Move into Quality “Differentiation” and Sterile Injectables
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Getting Organized for GDUFA: FDA Elevates Generic Review Activities Under New Director Geba
FDA’s Latest PR Push: Protecting the Reputation of Generic Drugs
The End of an Era: Lipitor, Blockbuster Drugs and the Waxman/Hatch Model

Topics

Advertisement
UsernamePublicRestriction

Register

PS081049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel